170 related articles for article (PubMed ID: 15153081)
1. Use of exogenous erythropoietin in critically ill patients.
MacLaren R; Gasper J; Jung R; Vandivier RW
J Clin Pharm Ther; 2004 Jun; 29(3):195-208. PubMed ID: 15153081
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
[TBL] [Abstract][Full Text] [Related]
3. Alternatives to blood product transfusion in the critically ill: erythropoietin.
Stubbs JR
Crit Care Med; 2006 May; 34(5 Suppl):S160-9. PubMed ID: 16617261
[TBL] [Abstract][Full Text] [Related]
4. The role of erythropoietin therapy in the critically ill.
Corwin HL
Transfus Med Rev; 2006 Jan; 20(1):27-33. PubMed ID: 16373185
[TBL] [Abstract][Full Text] [Related]
5. Use of epoetin alfa in critically ill patients.
Pajoumand M; Erstad BL; Camamo JM
Ann Pharmacother; 2004 Apr; 38(4):641-8. PubMed ID: 14966258
[TBL] [Abstract][Full Text] [Related]
6. Anemia in the critically ill.
Shander A
Crit Care Clin; 2004 Apr; 20(2):159-78. PubMed ID: 15135458
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human erythropoietin therapy in critically ill Jehovah's Witnesses.
Ball AM; Winstead PS
Pharmacotherapy; 2008 Nov; 28(11):1383-90. PubMed ID: 18956998
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial.
Corwin HL; Gettinger A; Pearl RG; Fink MP; Levy MM; Shapiro MJ; Corwin MJ; Colton T;
JAMA; 2002 Dec; 288(22):2827-35. PubMed ID: 12472324
[TBL] [Abstract][Full Text] [Related]
9. Anemia, transfusion, and phlebotomy practices in critically ill patients with prolonged ICU length of stay: a cohort study.
Chant C; Wilson G; Friedrich JO
Crit Care; 2006; 10(5):R140. PubMed ID: 17002795
[TBL] [Abstract][Full Text] [Related]
10. [Indications and limits of recombinant human erythropoietin in intensive care unit].
Ventré C; Rousseau S; Albanèse J; Leone M; Martin C
Ann Fr Anesth Reanim; 2004 Jul; 23(7):714-21. PubMed ID: 15324960
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: low donor chimerism predicts for poor response.
Vanstraelen G; Baron F; Willems E; Bonnet C; Hafraoui K; Frère P; Fillet G; Beguin Y
Exp Hematol; 2006 Jul; 34(7):841-50. PubMed ID: 16797411
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317].
Georgopoulos D; Matamis D; Routsi C; Michalopoulos A; Maggina N; Dimopoulos G; Zakynthinos E; Nakos G; Thomopoulos G; Mandragos K; Maniatis A;
Crit Care; 2005 Oct; 9(5):R508-15. PubMed ID: 16277712
[TBL] [Abstract][Full Text] [Related]
13. Anemia and red blood cell transfusion in the critically ill.
Corwin HL
Semin Dial; 2006; 19(6):513-6. PubMed ID: 17150052
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human erythropoietin use in intensive care.
Darveau M; Notebaert E; Denault AY; Bélisle S
Ann Pharmacother; 2002 Jun; 36(6):1068-74. PubMed ID: 12022910
[TBL] [Abstract][Full Text] [Related]
15. Anemia in critical illness.
Eckardt KU
Wien Klin Wochenschr; 2001 Feb; 113(3-4):84-9. PubMed ID: 11253745
[TBL] [Abstract][Full Text] [Related]
16. Understanding and managing anemia in critically ill patients.
Pearl RG; Pohlman A
Crit Care Nurse; 2002 Dec; Suppl():1-12; discussion 12-4; quiz 15-6. PubMed ID: 12518573
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients.
MacLaren R; Sullivan PW
Value Health; 2005; 8(2):105-16. PubMed ID: 15804319
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
[TBL] [Abstract][Full Text] [Related]
19. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach.
Rodríguez JN; Martino ML; Diéguez JC; Prados D
Haematologica; 1998 Jul; 83(7):616-21. PubMed ID: 9718866
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of randomized controlled trials in critically ill patients to evaluate the dose-response effect of erythropoietin.
Turaga KK; Sugimoto JT; Forse RA
J Intensive Care Med; 2007; 22(5):270-82. PubMed ID: 17895485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
